With No Lysine Kinase 3 (WNK3); A Target Enabling Package Dahkki Pinkas, D

Eará dahkkit: “…Pinkas, D…”

With no lysine kinase 3 (WNK3); A Target Enabling Package Dahkki Pinkas, D

Eará dahkkit: “…Pinkas, D…”

Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors Dahkki Suebsuwong, C, Pinkas, D, Ray, S, Bufton, J, Dai, B, Bullock, A, Degterev, A, Cuny, G

2-amino-2, 3-dihydro-1H-indene-5-carboxamide-based discoidin domain receptors 1 (DDR1) inhibitors: design, synthesis, and in vivo anti-pancreatic cancer efficacy Dahkki Zhu, D, Huang, H, Pinkas, D, Luo, J, Ganguly, D, Fox, A, Arner, E, Xiang, Q, Tu, Z, Bullock, A, Brekken, R, Ding, K, Lu, X

BTB domain mutations perturbing KCTD15 oligomerisation cause a distinctive frontonasal dysplasia syndrome Dahkki Miller, K, Cruz Walma, D, Pinkas, D, Tooze, R, Bufton, J, Richardson, W, Manning, C, Hunt, A, Cros, J, McGowan, S, Twigg, S, Chalk, R, Staunton, D, Johnson, D, Wilkie, A, Bullock, A

The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms Dahkki Fulcher, L, Bozatzi, P, Tachie-Menson, T, Wu, K, Cummins, T, Bufton, J, Pinkas, D, Dunbar, K, Shrestha, S, Wood, N, Weidlich, S, Macartney, T, Varghese, J, Gourlay, R, Campbell, D, Dingwell, K, Smith, J, Bullock, A, Sapkota, G

Design, synthesis, and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a dua... Dahkki Wang, Z, Zhang, Y, Pinkas, D, Fox, A, Luo, J, Huang, H, Cui, S, Xiang, Q, Xu, T, Xun, Q, Zhu, D, Tu, Z, Ren, X, Brekken, R, Bullock, A, Liang, G, Ding, K, Lu, X

With No Lysine Kinase 3 (WNK3); A Target Enabling Package Dahkki Bullock, A

Eará dahkkit: “…Pinkas, D…”